Larger studies are required to confirm that intratumor lactate is a bona fide indicator of HER2 mRNA expression levels and of the clinical benefit of anti‐HER2 treatments in the adjuvant and metastatic settings for patients with HER2‐positive BC. This evidence concerns the gene ERBB2 and breast cancer.